MCID: ANP031
MIFTS: 63

Anaplastic Thyroid Cancer

Categories: Rare diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Anaplastic Thyroid Cancer

MalaCards integrated aliases for Anaplastic Thyroid Cancer:

Name: Anaplastic Thyroid Cancer 53
Anaplastic Thyroid Carcinoma 53 59 6 73
Thyroid Carcinoma, Anaplastic 53
Thyroid Carcinoma Anaplastic 55
Thyroid Cancer, Anaplastic 53

Characteristics:

Orphanet epidemiological data:

59
anaplastic thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare endocrine diseases


Summaries for Anaplastic Thyroid Cancer

NIH Rare Diseases : 53 Anaplastic thyroid cancer(ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Most cases of anaplastic thyroid cancer are diagnosed in the sixth to seventh decade of life. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia), coughing, neck pain, and trouble breathing (dyspnea).Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits. Treatment of ATC is mostly palliative.

MalaCards based summary : Anaplastic Thyroid Cancer, also known as anaplastic thyroid carcinoma, is related to goiter and thyroid cancer, and has symptoms including dyspnea and hoarseness. An important gene associated with Anaplastic Thyroid Cancer is MIR18A (MicroRNA 18a
MiRNAs in a miR-17-92 cluster were overexpressed in ARO cells. We confirmed the overexpression of those miRNAs by Northern blot analysis in ARO and FRO cells. In 3 of 6 clinical ATC samples, miR-17-3p and miR-17-5p were robustly overexpressed in cancer lesions compared to adjacent normal tissue. To investigate the functional role of these miRNAs in ATC cells, ARO and FRO cells were transfected with miRNA inhibitors, antisense oligonucleotides containing locked nucleic acids. Suppression of miR-17-3p caused complete growth arrest, presumably due to caspase activation resulting in apoptosis. MiR-17-5p or miR-19a inhibitor also induced strong growth reduction, but only miR-17-5p inhibitor led to cellular senescence. On the other hand, miR-18a inhibitor only moderately attenuated the cell growth. Thus, we have clarified functional differences among the members of the cluster in ATC cells. In conclusion, these findings suggest that the miR-17-92 cluster plays an important role in certain types of ATCs and could be a novel target for ATC treatment.), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lymph node, and related phenotypes are anaplastic thyroid carcinoma and broad neck

Wikipedia : 76 Anaplastic thyroid cancer (ATC) is a form of thyroid cancer which has a very poor prognosis due to its... more...

Related Diseases for Anaplastic Thyroid Cancer

Diseases related to Anaplastic Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 goiter 30.1 NKX2-1 PAX8 TG TPO
2 thyroid cancer 27.2 BRAF CDH1 CDKN1A CTNNB1 EGF MET
3 thyroid hurthle cell adenoma 11.0 PIK3CA PTEN
4 nevus of ota 10.9 BRAF TP53
5 rare adenocarcinoma of the breast 10.9 PIK3CA TP53
6 thyroiditis 10.8
7 familial thyroid dyshormonogenesis 10.8 TG TPO
8 malignant spiradenoma 10.8 PIK3CA TP53
9 subacute lymphocytic thyroiditis 10.8 TG TPO
10 short-rib thoracic dysplasia 4 with or without polydactyly 10.8 CASP3 TP53
11 brain stem glioma 10.8 BRAF PIK3CA TP53
12 skin squamous cell carcinoma 10.7 BRAF PIK3CA TP53
13 giant cell glioblastoma 10.7 BRAF PTEN TP53
14 ovarian clear cell carcinoma 10.7 PIK3CA PTEN TP53
15 breast cystic hypersecretory carcinoma 10.7 CDH1 TG
16 cerebral convexity meningioma 10.7 CDH1 TP53
17 struma ovarii 10.7 BRAF NKX2-1 TG
18 ovarian germ cell teratoma 10.7 NKX2-1 TG
19 ovarian serous cystadenocarcinoma 10.7 BRAF PIK3CA TP53
20 actinic cheilitis 10.6 CDKN1A TP53
21 prostate transitional cell carcinoma 10.6 CTNNB1 PIK3CA
22 nodular goiter 10.6 BRAF TG TPO
23 small cell carcinoma 10.6 NKX2-1 PTEN TP53
24 vulvar intraepithelial neoplasia 10.6 CDH1 TP53
25 acral lentiginous melanoma 10.6 BRAF MET PTEN
26 testicular germ cell tumor 10.6 BRAF PTEN TP53
27 atypical follicular adenoma 10.6 CDKN1A TG TP53
28 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.6 TG TPO
29 urinary tract obstruction 10.6 CDH1 EGF PIK3CA
30 hyperplastic polyposis syndrome 10.6 BRAF TP53
31 bladder squamous cell carcinoma 10.6 BRAF PIK3CA PTEN TP53
32 pharynx cancer 10.6 CASP3 CDH1 TP53
33 female reproductive endometrioid cancer 10.5 CTNNB1 PTEN TP53
34 athyreosis 10.5 NKX2-1 PAX8 TG
35 papillary adenocarcinoma 10.5 CDH1 NKX2-1 TP53
36 pilocytic astrocytoma 10.5 BRAF PIK3CA PTEN TP53
37 salivary gland cancer 10.5 CASP3 MET PTEN
38 neonatal hypothyroidism 10.5 PAX8 TG TPO
39 oral cancer 10.5 CASP3 CDH1 TP53
40 bile duct carcinoma 10.5 CDH1 PIK3CA TP53
41 nervous system cancer 10.5 CASP3 CDKN1A TP53
42 hypothyroidism, congenital, nongoitrous, 2 10.5 NKX2-1 PAX8 TG
43 childhood hepatocellular carcinoma 10.5 CTNNB1 MET
44 li-fraumeni syndrome 10.5 CDKN1A PTEN TP53
45 tongue cancer 10.5 CDH1 CDKN1A TP53
46 parotid gland cancer 10.4 CDH1 MET PIK3CA
47 water-clear cell adenoma 10.4 PAX8 TG
48 helicobacter pylori infection 10.4 CASP3 MET TP53
49 peutz-jeghers syndrome 10.4 CTNNB1 PTEN TP53
50 small cell cancer of the lung 10.4 NKX2-1 PIK3CA PTEN TP53

Graphical network of the top 20 diseases related to Anaplastic Thyroid Cancer:



Diseases related to Anaplastic Thyroid Cancer

Symptoms & Phenotypes for Anaplastic Thyroid Cancer

Human phenotypes related to Anaplastic Thyroid Cancer:

59 32 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anaplastic thyroid carcinoma 59 32 obligate (100%) Obligate (100%) HP:0011779
2 broad neck 59 32 hallmark (90%) Very frequent (99-80%) HP:0000475
3 hoarse voice 59 32 hallmark (90%) Very frequent (99-80%) HP:0001609
4 nodular goiter 59 32 hallmark (90%) Very frequent (99-80%) HP:0005994
5 vocal cord paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0001605
6 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
7 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
8 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
9 upper airway obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0002781
10 laryngotracheal stenosis 59 32 frequent (33%) Frequent (79-30%) HP:0004894
11 pain 59 32 frequent (33%) Frequent (79-30%) HP:0012531
12 neoplasm of the lung 59 32 frequent (33%) Frequent (79-30%) HP:0100526
13 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
14 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
15 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
16 stridor 59 32 occasional (7.5%) Occasional (29-5%) HP:0010307
17 neoplasm of the skeletal system 59 32 occasional (7.5%) Occasional (29-5%) HP:0010622
18 abnormality of muscle morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0011805
19 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
20 tracheoesophageal fistula 59 32 very rare (1%) Very rare (<4-1%) HP:0002575
21 malignant neoplasm of the central nervous system 59 32 very rare (1%) Very rare (<4-1%) HP:0100836
22 goiter 59 Very frequent (99-80%)
23 dyspnea 59 Occasional (29-5%)

UMLS symptoms related to Anaplastic Thyroid Cancer:


dyspnea, hoarseness

GenomeRNAi Phenotypes related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 CTNNB1 ILK MET PIK3CA BRAF
2 Increased cell death HMECs cells GR00103-A-0 9.1 CASP3 CTNNB1 ILK PIK3CA PTEN TP53

MGI Mouse Phenotypes related to Anaplastic Thyroid Cancer:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 TP53 TG TPO BRAF CDH1 CASP3
2 endocrine/exocrine gland MP:0005379 10.43 TP53 TG TPO CDH1 CASP3 BRAF
3 cardiovascular system MP:0005385 10.4 TP53 BRAF CDH1 CASP3 CTNNB1 CDKN1A
4 homeostasis/metabolism MP:0005376 10.4 TPO TP53 TG CASP3 BRAF CDH1
5 cellular MP:0005384 10.39 TP53 CASP3 BRAF CTNNB1 CDKN1A CDH1
6 behavior/neurological MP:0005386 10.36 TP53 CASP3 BRAF CTNNB1 CDKN1A MET
7 digestive/alimentary MP:0005381 10.34 TP53 BRAF CDH1 CASP3 CDKN1A EGF
8 immune system MP:0005387 10.33 TPO TP53 CASP3 BRAF CDH1 CTNNB1
9 mortality/aging MP:0010768 10.32 TPO TP53 CASP3 BRAF CDH1 CTNNB1
10 embryo MP:0005380 10.29 TP53 BRAF CDH1 CTNNB1 CDKN1A ILK
11 craniofacial MP:0005382 10.26 TPO TP53 CASP3 BRAF CTNNB1 CDKN1A
12 integument MP:0010771 10.24 TP53 CASP3 BRAF CDH1 CTNNB1 CDKN1A
13 nervous system MP:0003631 10.2 TG TP53 CASP3 BRAF CTNNB1 CDKN1A
14 muscle MP:0005369 10.15 TP53 CASP3 BRAF CTNNB1 CDKN1A MET
15 neoplasm MP:0002006 10.13 TP53 BRAF CDH1 CTNNB1 CDKN1A NKX2-1
16 no phenotypic analysis MP:0003012 10.13 TP53 CDH1 CASP3 CDKN1A CTNNB1 ILK
17 hearing/vestibular/ear MP:0005377 10.11 TPO TP53 CASP3 BRAF CTNNB1 CDKN1A
18 normal MP:0002873 10.1 TP53 BRAF CDH1 CTNNB1 MET ILK
19 limbs/digits/tail MP:0005371 10.07 TPO TP53 CTNNB1 CDKN1A MET PAX8
20 reproductive system MP:0005389 10 TP53 CASP3 BRAF CDH1 CTNNB1 CDKN1A
21 renal/urinary system MP:0005367 9.97 TP53 CASP3 BRAF CTNNB1 CDKN1A ILK
22 pigmentation MP:0001186 9.85 TP53 CASP3 BRAF CTNNB1 ILK PTEN
23 respiratory system MP:0005388 9.81 TP53 CASP3 BRAF CTNNB1 CDKN1A ILK
24 skeleton MP:0005390 9.7 TPO TP53 CASP3 BRAF CTNNB1 CDKN1A
25 vision/eye MP:0005391 9.36 TP53 TPO BRAF CASP3 CDKN1A EGF

Drugs & Therapeutics for Anaplastic Thyroid Cancer

Drugs for Anaplastic Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
3
Fosbretabulin Investigational Phase 2, Phase 3,Phase 3,Phase 1 222030-63-9 5351387
4 Combretastatin Investigational Phase 2, Phase 3,Phase 3,Phase 1 82855-09-2
5 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
6 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
7 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
8
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
9
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
10
Everolimus Approved Phase 2 159351-69-6 6442177
11
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
12
Bevacizumab Approved, Investigational Phase 2 216974-75-3
13
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
14
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
15
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 84093 441203 2767
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
17
Hydroxyurea Approved Phase 2 127-07-1 3657
18
Tamoxifen Approved Phase 2 10540-29-1 2733526
19
Iodine Approved, Investigational Phase 2,Not Applicable 7553-56-2 807
20
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
21
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
22
Fluorouracil Approved Phase 2 51-21-8 3385
23
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
24
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
25
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Trametinib Approved Phase 2,Early Phase 1 871700-17-3 11707110
28
Lenvatinib Approved, Investigational Phase 2 417716-92-8
29
nivolumab Approved Phase 2 946414-94-4
30
Ceritinib Approved Phase 2 1032900-25-6
31
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
32
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
35
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
37 tannic acid Approved, Nutraceutical Phase 2
38
Doxil Approved June 1999 Phase 2,Phase 1 31703
39
Efatutazone Investigational Phase 1, Phase 2,Phase 2 223132-37-4
40 Folic Acid Antagonists Phase 2
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Nucleic Acid Synthesis Inhibitors Phase 2
43 Angiogenesis Inhibitors Phase 2,Phase 1
44 Angiogenesis Modulating Agents Phase 2,Phase 1
45 Anti-Bacterial Agents Phase 2,Phase 1
46 Vitamin B Complex Phase 2
47 Antibiotics, Antitubercular Phase 2,Phase 1
48 Immunosuppressive Agents Phase 2
49 Anti-Infective Agents Phase 2,Not Applicable
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
2 Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3 Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Unknown status NCT00804830 Phase 2 Bevacizumab
4 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
5 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
6 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed NCT01240590 Phase 1, Phase 2 Crolibulin;Cisplatin
7 A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Completed NCT00603941 Phase 1, Phase 2 CS7017;Paclitaxel
8 Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer Completed NCT00060242 Phase 2 fosbretabulin disodium
9 Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer Completed NCT00004089 Phase 2 fluorouracil;hydroxyurea;paclitaxel
10 Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
11 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Completed NCT03002623 Phase 2 CUDC-907
12 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
13 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
14 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
15 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
16 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
17 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
18 A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Recruiting NCT02244463 Phase 2 MLN0128
19 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer Recruiting NCT02726503 Phase 2 Lenvatinib
20 Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Recruiting NCT03565536 Phase 2 Nexavar
21 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Recruiting NCT02688608 Phase 2 Pembrolizumab
22 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Recruiting NCT02152137 Phase 2 efatutazone;paclitaxel
23 Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer Recruiting NCT02289144 Phase 2 Ceritinib
24 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Nab-paclitaxel - INDUCTION COHORT;Paclitaxel - INDUCTION COHORT;Vemurafenib - COHORT 1;Cobimetinib - COHORT 1;Atezolizumab - COHORT 1;Bevacizumab - COHORT 3;Nab-paclitaxel - COHORT 4;Paclitaxel - COHORT 4;Cobimetinib - COHORT 2;Atezolizumab - COHORT 2;Atezolizumab - COHORT 3;Atezolizumab - COHORT 4
25 Nivolumab Plus Ipilimumab in Thyroid Cancer Recruiting NCT03246958 Phase 2 Nivolumab;Ipilimumab
26 Phase I/II Study of PDR001 in Patients With Advanced Malignancies Recruiting NCT02404441 Phase 1, Phase 2
27 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
28 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Recruiting NCT02041260 Phase 2 Cabozantinib
29 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
30 A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Active, not recruiting NCT02657369 Phase 2 Lenvatinib 24 mg
31 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting NCT03211117 Phase 2 Docetaxel;Doxorubicin Hydrochloride
32 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting NCT01236547 Phase 2 Paclitaxel;Pazopanib Hydrochloride
33 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Active, not recruiting NCT00625846 Phase 2 Pazopanib Hydrochloride
34 Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Terminated NCT00115739 Phase 2 Imatinib
35 Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Terminated NCT00126568 Phase 2 sorafenib tosylate
36 Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer Terminated NCT00077103 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
37 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
38 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated NCT02012231 Phase 1, Phase 2 PLX8394
39 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
40 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
41 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
42 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
43 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
44 Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Recruiting NCT03122496 Phase 1 durvalumab;tremelimumab
45 A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting NCT02936102 Phase 1 FAZ053;PDR001
46 A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers Withdrawn NCT02516774 Phase 1 Adalimumab
47 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
48 Review of Multimodality Management of Anaplastic Thyroid Cancer Completed NCT00280852
49 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
50 Iodine I 131 in Treating Patients With Thyroid Cancer Completed NCT00416949 Not Applicable

Search NIH Clinical Center for Anaplastic Thyroid Cancer

Genetic Tests for Anaplastic Thyroid Cancer

Anatomical Context for Anaplastic Thyroid Cancer

MalaCards organs/tissues related to Anaplastic Thyroid Cancer:

41
Thyroid, Bone, Lymph Node, Lung, Liver, Endothelial, Nk Cells

Publications for Anaplastic Thyroid Cancer

Articles related to Anaplastic Thyroid Cancer:

(show top 50) (show all 279)
# Title Authors Year
1
Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2. ( 29734379 )
2018
2
CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer. ( 29849821 )
2018
3
Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. ( 29589394 )
2018
4
Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. ( 29534964 )
2018
5
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. ( 29517106 )
2018
6
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. ( 29517103 )
2018
7
miR-27b-3p is Involved in Doxorubicin resistance of Human Anaplastic Thyroid Cancer Cells via Targeting PPARI^. ( 29924913 )
2018
8
A Case of Pneumothorax after Treatment with Lenvatinib for Anaplastic Thyroid Cancer with Lung Metastasis. ( 29796324 )
2018
9
Bromodomaina89containing proteinA 4 is critical for the antiproliferative and proa89apoptotic effects of gambogic acid in anaplastic thyroid cancer. ( 29717765 )
2018
10
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. ( 29932104 )
2018
11
Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells. ( 29596381 )
2018
12
Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. ( 29409119 )
2018
13
Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis. ( 29487711 )
2018
14
Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft. ( 29563163 )
2018
15
Remarkable Presentation: Anaplastic Thyroid Carcinoma Arising from Chronic Hyperthyroidism. ( 29805818 )
2018
16
Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. ( 29774792 )
2018
17
LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. ( 29561707 )
2018
18
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. ( 29487290 )
2018
19
A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma. ( 29435119 )
2018
20
Dual effects for lovastatin in anaplastic thyroid cancer: the pivotal effect of transketolase (TKT) on lovastatin and tumor proliferation. ( 29502067 )
2018
21
Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin. ( 28128736 )
2017
22
SPC24 is critical for anaplastic thyroid cancer progression. ( 28423533 )
2017
23
Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. ( 28423545 )
2017
24
The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma. ( 27586674 )
2017
25
Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer. ( 29383121 )
2017
26
Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways. ( 28282720 )
2017
27
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent. ( 28030793 )
2017
28
Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. ( 28288903 )
2017
29
Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report. ( 28413394 )
2017
30
Role of KrA1ppel-like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer. ( 28920531 )
2017
31
MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. ( 28122310 )
2017
32
Effect of Slug-Mediated Down-Regulation of E-Cadherin on Invasiveness and Metastasis of Anaplastic Thyroid Cancer Cells. ( 28070118 )
2017
33
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. ( 28324060 )
2017
34
FOXD3 regulates anaplastic thyroid cancer progression. ( 28430585 )
2017
35
Comparison of sonographic characteristics of primary thyroid lymphoma and anaplastic thyroid carcinoma. ( 29268549 )
2017
36
h-prune affects anaplastic thyroid cancer invasion and metastasis. ( 27109060 )
2016
37
Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo. ( 27802204 )
2016
38
Targeting ubiquitin-specific protease 22 suppresses growth and metastasis of anaplastic thyroid carcinoma. ( 27145278 )
2016
39
The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. ( 26625205 )
2016
40
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). ( 27307592 )
2016
41
Involvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cells. ( 25773758 )
2016
42
Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3I^ signaling pathway activation. ( 27487122 )
2016
43
Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. ( 26289851 )
2016
44
Elucidation of the molecular mechanisms of anaplastic thyroid carcinoma by integrated miRNA and mRNA analysis. ( 27599582 )
2016
45
Description and Comparison of the Sonographic Characteristics of Poorly Differentiated Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. ( 27388812 )
2016
46
Riedel's Thyroiditis Mimicking as Anaplastic Thyroid Carcinoma: Unusual Presentation. ( 27651702 )
2016
47
Sustained Response to Vemurafenib in a BRAF<sup>V600E</sup>-Mutated Anaplastic Thyroid Carcinoma Patient. ( 27532222 )
2016
48
miR-206 inhibits metastasis-relevant traits by degrading MRTF-A in anaplastic thyroid cancer. ( 25955685 )
2015
49
Anaplastic Thyroid Carcinoma (ATC) with Superior Vena Cava (SVC) Syndrome, Cardiac Tamponade and Pleural Effusion: An Unusual Clinical Presentation. ( 25859509 )
2015
50
Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. ( 24687827 )
2015

Variations for Anaplastic Thyroid Cancer

ClinVar genetic disease variations for Anaplastic Thyroid Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802

Copy number variations for Anaplastic Thyroid Cancer from CNVD:

7 (show all 18)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18562 1 146514610 148102224 Gain Anaplastic thyroid cancer
2 57418 11 63321142 66212707 Gain CCND1 Anaplastic thyroid cancer
3 68082 12 47384342 48639263 Gain Anaplastic thyroid cancer
4 78984 13 61113549 63481793 Loss Anaplastic thyroid cancer
5 99673 16 28082639 28922556 Gain Anaplastic thyroid cancer
6 114238 17 45949240 46466966 Gain Anaplastic thyroid cancer
7 124653 19 11950033 12150103 Gain Anaplastic thyroid cancer
8 128382 19 40542097 41211643 Gain Anaplastic thyroid cancer
9 152529 20 31497814 33184582 Gain Anaplastic thyroid cancer
10 153944 20 41887694 44153298 Gain UBCH10 Anaplastic thyroid cancer
11 161614 22 19538297 19939137 Gain Anaplastic thyroid cancer
12 164302 22 36003989 36444264 Gain Anaplastic thyroid cancer
13 171639 3 170900000 182700000 Copy number PIK3CA Anaplastic thyroid cancer
14 182004 4 132076562 133123563 Loss Anaplastic thyroid cancer
15 188265 4 61317501 66095641 Loss Anaplastic thyroid cancer
16 211600 6 33165527 33494594 Gain Anaplastic thyroid cancer
17 225370 7 45400000 54000000 Amplification EGFR Anaplastic thyroid cancer
18 227803 7 72035816 72259198 Gain Anaplastic thyroid cancer

Expression for Anaplastic Thyroid Cancer

Search GEO for disease gene expression data for Anaplastic Thyroid Cancer.

Pathways for Anaplastic Thyroid Cancer

Pathways related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
2
Show member pathways
13.44 CASP3 CDKN1A EGF ILK MET PTEN
3
Show member pathways
13.39 BRAF CASP3 CDKN1A EGF MET PIK3CA
4
Show member pathways
13.15 CDKN1A EGF MET PIK3CA PTEN TP53
5
Show member pathways
13.06 BRAF CDKN1A CTNNB1 PAX8 TG TPO
6
Show member pathways
13.05 BRAF CASP3 CDH1 CTNNB1 MET TP53
7
Show member pathways
13 CASP3 CDKN1A CTNNB1 EGF MET PIK3CA
8
Show member pathways
12.94 BRAF EGF ILK MET PIK3CA PTEN
9
Show member pathways
12.92 BRAF CTNNB1 EGF ILK MET MIR34C
10 12.8 BRAF CASP3 EGF MET TP53
11
Show member pathways
12.78 BRAF CDH1 CTNNB1 EGF MET PIK3CA
12
Show member pathways
12.78 CDKN1A EGF MET PIK3CA PTEN TP53
13
Show member pathways
12.77 BRAF CDH1 CDKN1A EGF MET PIK3CA
14
Show member pathways
12.71 BRAF CASP3 CDH1 CTNNB1 MET PIK3CA
15
Show member pathways
12.64 CASP3 CDKN1A CTNNB1 PIK3CA PTEN TP53
16
Show member pathways
12.64 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
17
Show member pathways
12.58 BRAF CDH1 CDKN1A CTNNB1 EGF MET
18
Show member pathways
12.55 BRAF CDKN1A EGF MET PIK3CA TP53
19
Show member pathways
12.54 BRAF MET PIK3CA PTEN TP53
20
Show member pathways
12.5 CASP3 CTNNB1 MET PIK3CA TP53
21
Show member pathways
12.46 BRAF CASP3 CDH1 CTNNB1 EGF ILK
22 12.45 CDKN1A CTNNB1 PIK3CA TP53
23
Show member pathways
12.43 CASP3 CDKN1A MIR18A MIR19A PTEN TP53
24 12.42 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
25 12.33 CASP3 CDKN1A PIK3CA TP53
26
Show member pathways
12.3 BRAF CDH1 CTNNB1 PIK3CA
27
Show member pathways
12.29 CASP3 CDKN1A PTEN TP53
28 12.29 CDKN1A MET PAX8 TP53
29 12.25 BRAF CASP3 CDKN1A CTNNB1 MET PIK3CA
30 12.21 CDKN1A PIK3CA PTEN TP53
31
Show member pathways
12.2 CDKN1A CTNNB1 EGF PIK3CA PTEN
32
Show member pathways
12.17 BRAF CDKN1A EGF PIK3CA PTEN
33 12.17 BRAF CASP3 CDH1 CTNNB1 PTEN TP53
34 12.13 BRAF CDKN1A EGF PIK3CA TP53
35 12.13 CASP3 CDKN1A ILK MET PIK3CA PTEN
36
Show member pathways
12.12 CDH1 CDKN1A EGF MET PIK3CA
37 12.11 CDKN1A MET PTEN TP53
38
Show member pathways
12.1 CDKN1A MET PIK3CA PTEN TP53
39 12.08 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
40 12.05 CDKN1A CTNNB1 PIK3CA PTEN TP53
41 12 BRAF CDKN1A PTEN TP53
42 11.98 BRAF CASP3 CDH1 EGF
43 11.98 BRAF CDKN1A CTNNB1 EGF PTEN TP53
44 11.93 CDKN1A EGF PIK3CA
45
Show member pathways
11.93 CDH1 CTNNB1 EGF MET
46 11.92 CASP3 CDKN1A PIK3CA PTEN TP53
47 11.9 BRAF CASP3 CTNNB1
48 11.88 CDKN1A CTNNB1 PTEN
49 11.88 CASP3 MIR18A MIR19A MIR34C
50
Show member pathways
11.84 BRAF CASP3 PIK3CA

GO Terms for Anaplastic Thyroid Cancer

Cellular components related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 lamellipodium GO:0030027 8.92 CDH1 CTNNB1 ILK PIK3CA

Biological processes related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 CTNNB1 ILK MET PTEN TP53
2 MAPK cascade GO:0000165 9.92 BRAF EGF ILK MET
3 response to drug GO:0042493 9.89 CASP3 CDH1 CDKN1A CTNNB1 PTEN
4 positive regulation of transcription, DNA-templated GO:0045893 9.87 CDH1 CTNNB1 EGF ILK NKX2-1 PAX8
5 positive regulation of gene expression GO:0010628 9.85 BRAF CTNNB1 EGF NKX2-1 PTEN TP53
6 positive regulation of protein kinase B signaling GO:0051897 9.83 EGF ILK MET PIK3CA
7 negative regulation of apoptotic process GO:0043066 9.8 BRAF CASP3 CDKN1A ILK MET PTEN
8 canonical Wnt signaling pathway GO:0060070 9.78 CTNNB1 EGF PTEN
9 response to organic substance GO:0010033 9.73 CASP3 CDH1 CDKN1A PTEN
10 positive regulation of neuron apoptotic process GO:0043525 9.71 CASP3 CTNNB1 TP53
11 branching involved in ureteric bud morphogenesis GO:0001658 9.69 CTNNB1 ILK PAX8
12 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.65 ILK MIR19A PAX8
13 negative regulation of sprouting angiogenesis GO:1903671 9.63 MIR18A MIR19A MIR34C
14 replicative senescence GO:0090399 9.62 CDKN1A TP53
15 response to arsenic-containing substance GO:0046685 9.61 CDKN1A PTEN
16 hormone biosynthetic process GO:0042446 9.6 TG TPO
17 regulation of protein localization to cell surface GO:2000008 9.59 CTNNB1 EGF
18 regulation of calcium ion import GO:0090279 9.58 CTNNB1 EGF
19 regulation of axon regeneration GO:0048679 9.58 BRAF PTEN
20 response to X-ray GO:0010165 9.58 CASP3 CDKN1A TP53
21 signal transduction by p53 class mediator GO:0072331 9.56 CDKN1A TP53
22 cellular response to indole-3-methanol GO:0071681 9.55 CDH1 CTNNB1
23 entry of bacterium into host cell GO:0035635 9.33 CDH1 CTNNB1 MET
24 protein kinase B signaling GO:0043491 9.26 CDKN1A ILK PIK3CA PTEN
25 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG

Molecular functions related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 CTNNB1 MET TP53
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CASP3 CDKN1A
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 EGF MET PIK3CA
4 protein kinase binding GO:0019901 9.02 CDKN1A CTNNB1 ILK PTEN TP53

Sources for Anaplastic Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....